Custirsen
- Generic Name
- Custirsen
- Drug Type
- Biotech
- CAS Number
- 890056-27-6
- Unique Ingredient Identifier
- L26E95NLRK
- Background
Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in the treatment of primary brain tumors.
- Indication
Investigated for use/treatment in brain cancer and breast cancer.
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
- Conditions
- Cardiac Conduction and Repolarization
- Interventions
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT01874561
- Locations
- 🇺🇸
Teva Investigational Site 10565, Lenexa, Kansas, United States
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 700
- Registration Number
- NCT01630733
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇺🇸University Cancer Institute, Soynton Beach, Florida, United States
🇪🇸Hospital Universitario Doctor Peset, Valencia, Spain
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 630
- Registration Number
- NCT01578655
- Locations
- 🇺🇸
Georgia Cancer Specialists, P.C., Marietta, Georgia, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇿Krajská nemocnice Liberec a.s., Liberec, Czech Republic
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 1022
- Registration Number
- NCT01188187
- Locations
- 🇳🇱
Teva Investigational Site 852, Rotterdam, Netherlands
🇺🇸Teva Investigational Site 093, Marina del Rey, California, United States
🇺🇸Teva Investigational Site 100, Birmingham, Alabama, United States
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Conditions
- Hormone Refractory Prostate CancerCastrate-Resistant Prostate Cancer
- Interventions
- Drug: isotonic, 0.9% sodium chloride
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT01083615
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
- Conditions
- Breast CancerKidney CancerBladder CancerOvarian CancerUnspecified Adult Solid Tumor, Protocol SpecificLung CancerProstate Cancer
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 40
- Registration Number
- NCT00471432
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT00327340
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 82
- Registration Number
- NCT00258388
- Locations
- 🇨🇦
London Regional Cancer Program, London, Canada
🇨🇦BCCA - Cancer Centre for the Southern Interior, Kelowna, Canada
🇺🇸University of Washington, Seattle, Washington, United States
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 15
- Registration Number
- NCT00258375
- Locations
- 🇨🇦
British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2012-02-06
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT00138658
- Locations
- 🇨🇦
Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Cancer Centers of the Carolinas, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.